Levav Itzhak, Kohn Robert, Barchana Micha, Lipshitz Irena, Pugachova Inna, Weizman Abraham, Grinshpoon Alexander
Mental Health Services, Ministry of Health, Jerusalem, Israel.
J Affect Disord. 2009 Apr;114(1-3):316-20. doi: 10.1016/j.jad.2008.06.010.
Several epidemiological studies explored the risk for cancer among both persons with schizophrenia and their first-degree relatives, and among patients with bipolar disorder. No studies have yet explored the risk among persons with schizoaffective disorders.
Linkage analysis was conducted based on the psychiatric and the cancer national databases. Standardized incidence ratios (SIR) for aggregated cancer sites were calculated by comparing the incidence rates among patients in the psychiatric case register with schizoaffective disorders with the incidence rates in the Jewish-Israeli general population.
No significant alteration in cancer risk was found for both genders: males, SIR=1.11, 95% CI (0.48-1.73) and females, SIR=1.38, 95% CI (0.96-1.80).
Our sample was derived from patients with a history of psychiatric hospitalization. Putative factors such as diet, smoking and medications were not investigated.
Our study showed no significant increase in the risk for cancer in schizoaffective disorders. Those results appear to be positioned between the schizophrenia findings that show a lower risk for cancer and the bipolar disorder findings that show an increased risk.
多项流行病学研究探讨了精神分裂症患者及其一级亲属以及双相情感障碍患者患癌症的风险。尚未有研究探讨分裂情感性障碍患者的患癌风险。
基于国家精神病学和癌症数据库进行连锁分析。通过比较精神病例登记册中患有分裂情感性障碍的患者的发病率与以色列犹太普通人群的发病率，计算汇总癌症部位的标准化发病率（SIR）。
未发现两性患癌风险有显著变化：男性，SIR = 1.11，95% CI（0.48 - 1.73）；女性，SIR = 1.38，95% CI（0.96 - 1.80）。
我们的样本来自有精神科住院史的患者。未调查饮食、吸烟和药物等假定因素。
我们的研究表明，分裂情感性障碍患者患癌风险没有显著增加。这些结果似乎介于显示患癌风险较低的精神分裂症研究结果和显示患癌风险增加的双相情感障碍研究结果之间。
